In 2025, KFF reported that 19% of employers with 200+ workers and 43% with 5,000+ workers covered GLP-1s for weight loss, and employers are expected to revisit coverage and cost-containment strategies each year as demand remains high
It is one potentially modifiable biochemical burden that may coexist with methylation imbalance, oxidative stress, copper-zinc dysregulation, pyroluria, gut dysfunction or immune activation
Paluch AE, Boyer WR, Franklin BA, Laddu D, Lobelo F, Lee DC, et al
95% CI, 0.71-0.77)
Instead of several months, treatment may extend to a year or more